WindRose Health Investors

Investment decisions are led by Managing Partners C.J. Driessen and Oliver Moses, who co-founded the firm in 2000. Grant Chamberlain, a Managing Director, also serves on the senior investment team. The partnership group has remained small and stable, a deliberate structural choice that concentrates decision-making authority in a team whose entire careers have focused on healthcare investing.

No. WindRose does not invest in pre-revenue biotech, pharmaceutical drug development, or clinical-stage life sciences companies. Its investment focus is on healthcare services, pharmaceutical services and outsourcing, and medical technology products — businesses with established reimbursement models and existing revenue streams. The firm explicitly targets middle-market companies with $10 million to $50 million of EBITDA rather than unproven science.

The firm targets control-oriented growth equity and buyout investments in established middle-market healthcare companies. It does not participate in venture capital or seed-stage investing. WindRose's typical platform investment involves acquiring a controlling interest in a profitable North American healthcare business with existing management teams, then pursuing add-on acquisitions to build scale.

WindRose executes direct platform investments and add-on acquisitions. Historically, the firm has not operated as a fund-of-funds or allocated capital to third-party healthcare PE funds. Its limited partnership agreements focus capital deployment on direct control positions in operating companies, though co-investment alongside other sector-specialist PE firms occasionally occurs on larger transactions.

WindRose Health Investors VI closed at approximately $1.5 billion in January 2025, exceeding its $1.2 billion target and representing a material step up from Fund V's $1.2 billion hard cap reached in 2021. The oversubscribed final close resulted from strong demand among existing institutional LPs seeking additional healthcare specialization and from the firm's realization track record in provider services and pharma outsourcing platforms over the preceding cycle.